Stephens Investment Management Group LLC Purchases 70,875 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Stephens Investment Management Group LLC increased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 495,970 shares of the medical equipment provider’s stock after buying an additional 70,875 shares during the period. Stephens Investment Management Group LLC’s holdings in BioLife Solutions were worth $12,875,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of BLFS. Rockefeller Capital Management L.P. boosted its position in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares during the last quarter. State Street Corp raised its stake in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the period. D.A. Davidson & CO. purchased a new position in shares of BioLife Solutions in the 3rd quarter worth about $1,018,000. Alpha DNA Investment Management LLC bought a new position in BioLife Solutions during the third quarter valued at about $467,000. Finally, Geode Capital Management LLC increased its holdings in BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In related news, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,278 shares of company stock valued at $1,199,987 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $26.10 on Monday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $29.55. The stock has a market cap of $1.21 billion, a PE ratio of -24.62 and a beta of 1.91. The stock has a fifty day moving average of $26.76 and a 200-day moving average of $25.23.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on BLFS shares. Benchmark reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum increased their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.